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Summary Aerobic sensitivity to indoloquinone E09 has been shown to correlate with cellular levels of the
two-electron reducing enzyme DT-diaphorase. However, little is known about the relative roles of one- and
two-electron reducing enzymes in the hypoxic cytotoxicity of E09. We have characterised a panel of 23 human
tumour cell lines for both bioreductive enzyme activities and aerobic sensitivity to E09. Eight cell lines were
then selected for a comparison of aerobic and hypoxic sensitivities. Activities of DT-diaphorase showed a wide
range (> 10,000-fold), while activities of the one-electron reducing cytochrome b5 and cytochrome P450
reductases were generally lower and showed only a 15- and 25-fold range respectively. The aerobic cytotoxicity
of E09 was clearly related to the cellular levels of DT-diaphorase (r = 0.87), with higher levels giving increased
sensitivity, but not to the levels of one-electron reducing enzymes. In contrast, there was no relationship
between sensitivity to BCNU, cisplatin or the bioreductive agent SR 4233 (tirapazamine) and activities of any
of these reducing enzymes. Under hypoxic conditions sensitivity to E09 was markedly increased in cell lines
with low levels of DT-diaphorase activity, while cell lines with high levels show only a small increase in
sensitivity. This is reflected by a clear correlation (r = 0.98) between cellular DT-diaphorase activity and the
ratio of aerobic to hypoxic sensitivity to E09. However, we have now for the first time demonstrated an
inverse correlation (r = 0.93) between the cellular activity of DT-diaphorase and hypoxic sensitivity to E09,
that is sensitivity decreases with increasing DT-diaphorase activity. Moreover, this correlation was lost when
cells were exposed to drug in the presence of dicoumarol, supporting an involvement of DT-diaphorase in this
relationship. These observations question the previously straightforward role for DT-diaphorase in the
metabolic activation of E09. Whereas DT-diaphorase is associated with increased toxicity in air, it appears to
reduce the cytotoxicity of E09 in hypoxic conditions. This suggests either that the one-electron reduction
product of E09 metabolism, the semiquinone, is more toxic than the two-electron reduction product, the
hydroquinone, or that the hydroquinone is not cytotoxic and aerobic toxicity is due to the transient
appearance of the semiquinone upon back oxidation of the hydroquinone.
Indoloquinone E09 is a novel bioreductive agent currently
undergoing phase I/II evaluation under the auspices of the
EORTC (Schellens et al., 1994). It is structurally related to
mitomycin C but is less myelosuppressive (Hendriks et al.,
1993). Mitomycin C is relatively cytotoxic under aerobic
conditions and shows little increase in cytotoxicity under
hypoxic conditions (Stratford & Stephens, 1989; Workman,
1992). It lacks therefore, the selectivity for hypoxic areas
which are thought to be present in some solid tumours and
to confer radioresistance on these cancers (Coleman, 1988;
Gatenby et al., 1988). While mitomycin C shows only a
modest increase in activity under hypoxic conditions, sen-
sitivity to E09 can be increased by up to 1,000-fold (Plumb
& Workman, 1994; Robertson et al., 1994).
DT-diaphorase is an obligate two-electron reducing
enzyme known to play a role in the detoxification of simple
quinone-containing compounds (lyanagi & Yamazaki, 1970).
E09 is a good substrate for DT-diaphorase, being reduced at
about a sixth of the rate for the benchmark quinone
menadione but 5,000-fold faster than mitomycin C (Walton
et al., 1991). Following our observation that in a pair of
mouse solid colon carcinomas in vivo E09 showed much
greater activity against the tumour possessing high levels of
DT-diaphorase and a similar relationship for two human
colon carcinoma lines in culture (Walton et al., 1992), a
number of reports have shown a correlation between the
cellular activity of DT-diaphorase and aerobic sensitivity to
E09 in vitro (Phillips et al., 1992; Robertson et al., 1992;
Smitskamp-Wilms et al., 1994). That sensitivity to E09 is
related to the activity of DT-diaphorase suggests that two-
electron reduction represents a pathway for the activation of
this bioreductive quinone which can be exploited in the clinic
(Workman & Stratford, 1993), since levels of DT-diaphorase
have been reported to be increased in a number of tumour
types (Riley & Workman, 1992). However, the activity of
DT-diaphorase is generally much greater than that of the
one-electron reducing enzymes, such as cytochrome P450
reductase and cytochrome b5 reductase, and it is not clear
precisely what level of activity of DT-diaphorase is required
to induce sensitivity to E09. Furthermore, while hypoxia is
thought to be a phenomenon restricted to poorly vascu-
larized tumours, DT-diaphorase is widely distributed
throughout the body and high levels are observed in the liver,
kidney and intestine (Ernster, 1967), suggesting that these
tissues may be sensitive to the aerobic toxicity of E09.
Indeed, the dose-limiting toxicity of E09 is proteinuria
(Schellens et al., 1994), possibly indicative of damage to the
kidney following DT-diaphorase activation in this enzyme-
rich organ, while the absence of myelosuppression is consis-
tent with the very low levels of this enzyme in the bone
marrow (Lewis et al., 1993).
Previously, we reported that the human colon carcinoma
cell line BE, which lacks DT-diaphorase activity, is relatively
resistant to the aerobic toxicity of E09 while the HT29
human colon tumour line, which has high levels of DT-
diaphorase, is relatively sensitive to the drug (Walton et al.,
1992). However, we went on to demonstrate that under
hypoxic conditions HT29 shows little increase in sensitivity
to E09 while that for BE is increased by over 1,000-fold,
such that BE becomes more sensitive than HT29 (Plumb &
Workman, 1994). These results suggested that in the absence
of DT-diaphorase E09 could be activated under hypoxic
conditions, presumably by one-electron reduction, to a
similar or even greater extent than by DT-diaphorase. Since
the two cell lines are equally sensitive to a range of other
cytotoxic drugs, we suggested that this could indicate that the
one-electron reduction product, the semiquinone, is more
cytotoxic than the two-electron reduction product, the hydro-
quinone. This raised a question as to the nature of the
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cytotoxic intermediate of E09 metabolism (Plumb & Work-
man, 1994).
In the present paper we have extended our studies on the
relative roles of one- and two-electron reducing enzymes in
the bioactivation of E09 to include a panel of 23 human
tumour cell lines with a range of activities of DT-diaphorase.
While our results support the correlation between levels of
DT-diaphorase and sensitivity to E09 in air, we now show
for the first time that DT-diaphorase appears to protect cells
from the toxicity of E09 under hypoxic conditions. We
propose that the semiquinone metabolite of E09 may be the
cytotoxic entity under both aerobic and hypoxic condi-
tions.
Materials and methods
Chemicals
cis-Diamminedichloroplatinum(II) (cisplatin), menadione, 3-
(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), cytochrome c, dicoumarol, NADH and NADPH
were purchased from Sigma (Poole, Dorset, UK). E09 was
provided by the New Drug Development Office of the
EORTC and tirapazamine (SR 4233, WIN 59075) was kindly
donated by Drs M. Tracy and W.W. Lee of SRI Interna-
tional (Menlo Park, CA, USA). BCNU was obtained from
the US National Cancer Institute.
Cell lines
Details and origins of the cell lines used are shown in Table
I. The breast and ovarian cell lines were grown as monolayer
cultures in RPMI-1640 medium (Life Technologies, Paisley,
UK) supplemented with glutamine (2 mM), fetal calf serum
(10%) and, for the ovarian cell lines, insulin (0.25
units ml-'). The small-cell lung cancer cell lines were grown
as non-adherent cultures in RPMI-1640 medium with 10%
fetal calf serum. The glioma and non-small-cell lung cancer
cell lines were grown as adherent cultures in a mixture of
Ham's FlO and Dulbecco's modified Eagle medium (50:50,
Life Technologies) supplemented with glutamine (2 mM) and
fetal calf serum (10%).
Cytotoxicity assay
Sensitivities of the cell lines to a number of cytotoxic drugs
was determined under aerobic conditions by a tetrazolium
dye-based microtitration assay as described previously
(Plumb et al., 1989). Briefly, adherent cells were plated out at
a density of 103 cells per well in 96-well flat-bottomed plates
(Linbro from ICN Biomedicals, High Wycombe, Bucks, UK)
and allowed to attach and grow for 3 days. Non-adherent
cells were plated out in a total volume of 100psl and 100 gil of
drug at twice the final concentration was added immediately.
Cells were exposed to the cytotoxic drugs for 24 h and then
fed with fresh medium daily for 3 days. On the fourth day,
cells were fed with medium containing HEPES buffer
(10 mM) and MTT (50 gil, 5 mg ml-') was added to each well.
Plates were incubated in the dark at 37°C for 4 h, medium
and MTT removed and MTT-formazan crystals dissolved in
dimethylsulphoxide (200 gil per well). Glycine buffer (25 gIl
per well, 0.1 M, pH 10.5) was added and the absorbance
measured at 570 nm in a multiwell plate reader (model 3550
EIA reader, Bio-Rad, Hemel Hempstead, Herts, UK).
A typical dose-response curve consisted of eight drug con-
centrations and four wells were used per drug concentration.
Within an experiment triplicate determinations were made
for each treatment and the three dose-response curves were
obtained from separate plates. Results are expressed in terms
of the drug concentration required to kill 50% of the cells
(ID50), estimated as the absorbance value equal to 50% of
that of the cells in the control untreated wells.
Hypoxic cytotoxicity assay
For estimation of the oxic-hypoxic cytotoxicity ratio, adhe-
rent cells were grown on glass for drug exposure and sensi-
tivity was determined by a clonogenic assay. Cells were
plated out at a density of 2 x 105 cells per 5 cm glass Petri
dish and allowed to attach and grow for 2 days. The medium
was removed from the dishes and replaced with 2.5 ml of
fresh medium containing the drug. They were exposed to
drug for 3 h in a humidified atmosphere under oxic (2%
carbon dioxide in air) or hypoxic (2% carbon dioxide in
nitrogen) conditions. After removal of the medium cells were
detached with trypsin (0.25% trypsin + EDTA I mM in
phosphate-buffered saline PBS) and resuspended in fresh
medium. Cells from the control, untreated, dishes were
Table I Characteristics and sources of the 23 human tumour cell lines
Tumour origin Cell line Characteristics Source
Breast MDAMB231 Adenocarcinoma ATCC
ZR75 Adenocarcinoma ATCC
MCF7 Adenocarcinoma Dr K. Cowan, NCI, USA
MCF7/Adr Doxorubicin resistant
Glioma GUVW Fibroblastic Medical Oncology, Glasgow
U251 Epithelioid Dr B. Westermark, Uppsala
SB18 Fibroblastic Dr J. Pilkington, Institute of
Psychiatry, London
GCCM Fibroblastic Medical Oncology, Glasgow
T98G Glioblastoma ATCC
Ovary A2780 Adenocarcinoma Dr R.F. Ozols,
2780CP Cisplatin resistant Fox Chase Cancer Centre
2780AD Doxorubicin resistant Pennsylvania, USA
OVCAR3 Adenocarcinoma
OVCAR4 Adenocarcinoma
OVCAR5 Adenocarcinoma
Lung H69 Small-cell ATCC
H69LXIO Doxorubicin resistant Dr P. Twentyman
MRC Cambridge
H187 Small-cell ATCC
H128 Small-cell ATCC
CALU-3 Adenocarcinoma ATCC
SK-MES Squamous ATCC
LDAN Squamous Medical Oncology, Glasgow
A549 Type II properties ATCC1138 J.A. PLUMB et al.
counted, diluted and plated out into plastic Petri dishes
(6cm, Nunclon from Life Technologies) at a density of 103
cells per dish. Cells from the drug-treated dishes were diluted
and plated out as for the control dishes. After incubation for
10 days at 37°C, colonies were fixed in methanol, stained
with crystal violet (0.1%) and colonies of more than 50 cells
counted. Drug sensitivity is expressed as the ID50, which is
the concentration required to reduce the number of colonies
to 50% of that in the control, untreated, dishes.
For the non-adherent small-cell lung cancer cell lines
hypoxic sensitivity was determined by MTT dye reduction
(Plumb et al., 1989; Stratford & Stephens, 1989). Cells were
plated out in a total volume of 200 p1 into glass inserts in
24-well plates at a density of lO'cellsml-'. E09 (50.tl) was
added at five times the final concentration. They were in-
cubated for 3 h at 37°C under oxic or hypoxic conditions.
The medium was then changed and cells were fed daily for
the following 3 days. They were then exposed to MTT for
4 h and processed as usual except that the contents of the
wells were transferred to cuvettes and absorbance at 570 nm
recorded in a spectrophotometer.
Estimation of enzyme activities
Cells were grown in 75 cm2 flasks, trypsinised if required, and
washed twice with ice-cold PBS. They were resuspended in
I ml of PBS containing aprotonin (1%), sonicated on ice and
the suspension centrifuged at 4°C in an Eppendorf microfuge.
DT-diaphorase activity in the supernatant was determined
spectrophotometrically by following the reduction of cyto-
chrome c at 550 nm using a modification of the method of
Ernster (1967). A sample of the supernatant (5 tsl) was added
to the reaction mixture, which contained cytochrome c
(77 JAM), menadione (20 JAM) or E09 (50 SIM) as the inter-
mediate electron acceptor, NADPH (2 mM) as co-factor and
bovine albumin (0.14%, w/v). Reactions were performed at
37°C in a total volume of 1 ml Tris-HCl buffer (50 mM,
pH 7.4) in the presence and absence of the inhibitor
dicoumarol (100wM). DT-diaphorase activity was taken as
the activity that could be inhibited by dicoumarol and is
reported as nmol of cytochrome c (e 21.1 x I03M cm-')
reduced per minute per 106 cells.
Cytochrome P450 reductase and cytochrome b5 reductase
activities were determined as above except that the
intermediate electron acceptor was omitted from the reaction
mixture and the co-factor used was NADPH for cytochrome
P450 reductase and NADH for cytochrome b5 reductase.
Statistical analysis
Statistically significant differences were determined by
Student's t-test.
Results
Activity ofDT-diaphorase, cytochrome b5 reductase and
cytochrome P450 reductase
The activities of DT-diaphorase, cytochrome b5 reductase
and cytochrome P450 reductase in the 23 human tumour cell
lines are shown in Table II. There is a wide range
(1.3-13,571 nmol min-' 106 cells, > 10,000-fold) of activities
of DT-diaphorase, with the most marked difference observed
between the small-cell and non-small-cell lung cancer cell
lines. However, within each tumour type there is a range of
activities. In contrast, activities of cytochrome b5 reductase
and cytochrome P450 reductase show only a 15 (11.5-
170.5 nmolmin-' 106cells) and 25 (5.2-127.5nmol min-'
10-6 cells) fold range respectively. these two enzyme activities
are lower than those of DT-diaphorase except in the case of
seven of the cell lines in which the activity of DT-diaphorase
is less than 35 nmol min-' 10-6 cells. Although the two drug-
resistant variants of A2780 show significantly increased
activities of DT-diaphorase (2780AD, 1.9-fold, P<0.01;
2780CP, 3.6-fold, P<0.01), this is not the case for MCF7/
Adr and H69LX1O compared with their parent lines.
Aerobic drug sensitivities of the cell lines
Sensitivities of the cell lines to E09, SR 4233, BCNU and
cisplatin are also shown in Table II. As shown clearly in
Figure 1 there is a correlation (r = 0.87) between sensitivity
to E09 and the cellular activity of two-electron reducing
Table II Activities (nmol min-' 10-6 cells) of DT-diaphorase, cytochrome b5 reductase and cytochrome P450 reductase in the human tumour
cell lines. Also shown are the sensitivites of the cell lines to E09, SR 4233, BCNU and cisplatin. Sensitivity was determined by an MTT-based
cytotoxicity assay. Cells were exposed to drug for 24 h and sensitivity is expressed as the ID_0 concentration. Results are the mean ± s.e.m. of
triplicate estimations
Enzyme activity (nmolmin-O-6 cells) ID50
Tumour Cell line DT-diaphorase bS reductase P450 reductase E09 (nM) SR4233 (pM) BCNU (gM) Cisplatin (IM)
Breast MDAMB231 6 4 105.0± 11.6 101.5 ± 4.6 320.0± 11.5 290.0± 2.7 55.3 ± 2.3 5.0± 0.4
ZR75 1096± 144 40.0± 1.3 31.0± 2.0 32.0± 3.1 1400± 77 188.3 ± 21.3 8.7± 0.4
MCF7 4476 ± 89 37.0 ± 2.6 29.0 ± 1.7 4.0 ± 0.3 65.0 ± 4.8 88.0 ± 10.4 1.2 ± 0.1
MCF7/Adr 35 ± 2 50.5 ± 3.0 35.5 ± 3.9 55.0 ± 2.9 940.0 ± 97.0 251.7 ± 1.7 6.1 ± 0.2
Glioma GUVW 166 31 119.5± 16.0 70.0± 2.6 150.0± 11.5 205.0± 25.5 38.0± 3.5 0.8±0.1
U251 298 ± 80 102.0 ± 4.1 74.5 ± 5.4 2.0 ± 0.2 42.5 ± 9.2 18.2 ± 1.1 0.08 ± 0.003
SB18 685 81 80.5 ± 4.9 54.0 ± 2.2 25.0 ± 1.3 593.0 ± 60.0 61.0 ± 11.6 0.7 ± 0.2
GCCM 961 + 323 170.5 ± 4.5 127.5 ± 8.8 22.0 ± 1.2 708.5 ± 124.5 59.3 ± 2.0 1.6 ± 0.3
T98G 9334 547 106.5 ± 6.2 73.5 ± 3.4 10.0 ± 1.0 160.0 ± 6.0 221.7 ± 19.2 3.9 ± 0.2
Ovary OVCAR4 225 ± 108 73.0 ± 2.8 39.0 ± 3.9 180.0 ± 21.9 266.5 ± 24.5 102.7 ± 4.1 2.3 ± 0.3
A2780 554 ± 38 36.5 ± 7.0 15.5 ± 0.7 2.0± 0.1 4.5 ± 0.6 9.7 ± 1.0 0.2± 0.01
2780AD 1023 ± 40 18.0±0.7 12.5±0.8 10.0±4.4 74.5± 10.7 33.0± 1.2 1.1 ±0.1
OVCAR3 1768 ± 202 128.0 ± 8.4 111.5 ± 9.6 16.0 ± 2.7 68.5 ± 12.9 225.0 ± 40.1 0.8 ± 0.04
2780CP 2014 _ 225 41.0 ± 2.5 25.0 ± 2.3 14.0 ± 0.4 44.5 ± 3.5 49.7 ± 2.9 3.5 ± 0.2
OVCAR5 4109 195 87.0 ± 5.8 69.5 ± 4.8 13.0 ± 1.2 77.5 ± 8.2 113.3 ± 4.4 1.5 ± 0.3
Lung H69LX10 1.3 0.5 53.0 ± 2.1 35.0 ± 1.5 2450 ± 148 46.5 ± 7.0 4.6 ± 0.6 1.5 ± 0.2
H69 2.0 1.0 61.5 ± 4.8 74.0 ± 3.4 2467 ± 87 13.5 ± 3.6 5.5 ± 1.2 2.2 ± 0.6
H187 6.6 0.9 12.2 ±0.4 5.5 ± 0.1 425.0± 128.0 107.0± 10.2 7.0± 0.4 0.8 ± 0.1
H128 9.9 1.4 11.5 ± 0.5 5.2 ± 0.1 646.0 ± 104.0 167.0 ± 68.0 174.0 ± 54.9 8.0 ± 2.4
CALU-3 30 ± 3 109.5 ± 9.5 64.0 ± 7.6 97.0 ± 8.7 59.0 ± 3.9 158.3 ± 3.3 4.3 ± 0.2
SK-MES 1849 103 158.0 ± 18.7 67.0 ± 9.7 8.0± 0.3 110.0 ± 8.1 2.6 ± 0.4 2.9 ± 0.3
LDAN 2066 140 105.5 ± 14.4 74.5 ± 2.0 12.0 ± 0.4 58.5 ± 4.6 151.7± 10.9 3.5 ± 0.1
A549 13571 _ 1365 115.5± 5.5 79.5±9.0 4.0±0.3 98.0± 12.3 113.4± 8.3 2.7±0.2DT-DIAPHORASE AND E09 TOXICITY 1139
DT-diaphorase. Increased sensitivity to E09 is associated
with elevated levels of DT-diaphorase activity. No such cor-
relation is apparent for SR 4233 (r = 0.07), BCNU (r = 0.39)
and cisplatin (r = 0.10). Furthermore, there is no relationship
between the activities of the one-electron reducing enzymes,
cytochrome b5 reductase (r = 0.26) and cytochrome P450
reductase (r = 0.19), and sensitivity to E09 or to any of the
other three drugs (Table II). Of note, two of the cell lines,
U251 and A2780, are markedly more sensitive to E09 than is
predicted from their levels of DT-diaphorase activity (Figure
1, Table II). However, these two cell lines are also the most
sensitive to cisplatin and both are relatively sensitive to
BCNU and SR 4233, suggesting an overall sensitivity to
DNA-damaging agents. The drug-resistant variants of A2780
are cross-resistant (by 5 to 7-fold) to E09, as is the
doxorubicin-resistant breast cell line MCF7/Adr (14-fold),
but this is not the case for the doxorubicin-resistant small-cell
lung cancer cell line H69LXIO. For 2780AD and 2780CP this
cross-resistance correlates with increased activities of DT-
diaphorase.
Sensitivity to E09 under hypoxic conditions
For each tumour type sensitivity to E09 under hypoxic
conditions was determined for the cell lines with the highest
and lowest levels of DT-diaphorase activity (Table III). DT-
diaphorase activity was determined with either menadione or
E09 as the intermediate electron acceptor. Activities
measured with E09 as the substrate were much lower than
those for menadione, but the relative activities for the eight
cell lines were consistent for the two substrates (r = 0.97,
Figure 2).
For each pair of cell lines within a given tumour type, the
increase in sensitivity to E09 under hypoxic conditions was
greatest for the cell line with lowest level of DT-diaphorase
activity (Table IV). This is, for example, most obvious in the
two breast lines, in which the enzyme-rich MCF7 cell line
gave an increase in sensitivity of only 2-fold, whereas the low
DT-diaphorase line MDAMB231 exhibited an increase of
757-fold. Note that for the cells showing the greatest enzyme
activity, the A549 lung cancer line, there was no change at all
in sensitivity to E09 under hypoxic compared with aerobic
conditions. Furthermore, there was a clear correlation
(r = 0.98) between DT-diaphorase activity and the
aerobic-hypoxic cytotoxicity ratio (Table IV, Figure 3).
Again as seen for the larger series, under aerobic conditions,
the cell lines with the highest levels of DT-diaphorase activity
were most sensitive to E09 (r = 0.95, Figure 4a). Impor-
tantly, however, under hypoxic conditions these cell lines
were the least sensitive to E09 and the reverse correlation
was seen (r = 0.93, Figure 4b).
Effect ofdicoumarol on the aerobic and hypoxic toxicity of
E09
Sensitivity to E09 was also determined in the presence of
dicoumarol (200gAM), an inhibitor of DT-diaphorase (Table
III). This concentration had no effect on cell survival.
Dicoumarol decreased the aerobic sensitivity of all eight cell
lines by 2.5- to 5.1-fold (Table IV) but the correlation
between sensitivity to E09 and activity of DT-diaphorase
remained (Figure 4a). In contrast, the hypoxic sensitivity of
seven of the cell lines was increased in the presence of
dicoumarol, and the increase was greatest for the cell lines
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Figure 1 Activity of DT-diaphorase, determined with menadione
as the intermediate electron acceptor, and sensitivity to E09
(r = 0.87) for the 23 human tumour cell lines. Results are those
presented in Table II.
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Figure 2 Relationship (r = 0.97) between the activity of DT-
diaphorase determined with menadione as the intermediate elec-
tron acceptor and that determined with E09. Results are shown
for the four pairs of the cell lines and are those presented in
Table III.
Table III Activities of DT-diaphorase and sensitivity to E09 determined in the presence (aerobic) and absence (hypoxic)
of air for four pairs ofcell lines selected as those with the highest and lowest levels of DT-diaphorase activity from each of
the four tumour types. DT-diaphorase activity (nmol min'- 10-6 cells) was determined with either menadione or E09 as
the intermediate electron acceptor. Sensitivity to E09 (ID50) was determined by a clonogenic assay and cells were exposed
to drug for 3 h. Also shown is the sensitivity to E09 determined in the presence of dicoumarol (200JAM). Results are the
mean ± s.e.m. of triplicate estimations
DT-diaphorase ID50 (nM) E09
(nmolmin-' 10-6 cells) ID50 (nM) E09 + dicoumarol
Tumour Cell line Menadione E09 Aerobic Hypoxic Aerobic Hypoxic
Breast MDAMB231 6 4 1.5 0.3 18167 1202 24 7 60333 ± 3180 9± 3
MCF7 4476±89 57.0±2.0 166 11 81 16 532± 141 6±2
Glioma GUVW 166±31 15.0±2.6 2050±226 38 10 9400± 1137 22±7
T98G 9334 547 113.5 6.6 290 20 117 26 1467 ± 83 33 ± 11
Ovary OVCAR4 225 108 13.0 0.6 1983 169 49 2 7967 ± 328 21 ± 6
OVCAR5 4109 195 50.5 3.6 337 3 58 11 1673 23 8 2
Lung CALU-3 30 ± 3 10.0 ± 0.3 2085 ± 43 32 ± 12 5233 ± 657 30 ± 8
A549 13571 1365 193.5 15.2 238 30 233 48 590 25 37 9
I . ... .. _ . . . .... . . _ . . . ... ...._1140 J.A. PLUMB et al.
Table IV Hypoxic cytotoxicity ratio for E09 (aerobic ID50 . hypoxic ID50) in the eight
cell lines shown in Table III. Also shown is the decrease in aerobic and increase in
hypoxic sensitivity to E09 in the presence of dicoumarol
ID50 E09
Aerobic Aerobic + dicoumarol Hypoxic
Tumour Cell line hypoxic aerobic hypoxic + dicoumarol
Breast MDAMB231 757.0 3.3 2.7
MCF7 2.1 3.2 13.5
Glioma GUVW 54.0 4.6 1.7
T98G 2.5 5.1 3.6
Ovary OVCAR4 40.5 4.0 2.3
OVCAR5 5.8 5.0 7.3
Lung CALU-3 65.2 2.5 1.1
A549 1.0 2.5 6.3
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Figure 3 Correlation between the activity of DT-diaphorase and
the hypoxic cytotoxicity ratio for E09 (r = 0.98). DT-diaphorase
activity was determined with E09 as intermediate electron accep-
tor and the hypoxic sensitisation ratio is the sensitivity of the cell
line to E09 in air divided by the hypoxic sensitivity to E09.
Results are those shown in Table III.
with the highest levels of DT-diaphorase activity (Table IV).
In the presence of dicoumarol there was no relationship
between DT-diaphorase activity and the hypoxic sensitivity
to E09 (Figure 4b).
Discussion
We have confirmed, in a large panel of breast, glioma,
ovarian and lung tumour cell lines, a clear correlation
between cellular levels of DT-diaphorase and sensitivity in air
to E09 (Table II, Figure 1). For cell lines that have low
activities of DT-diaphorase, sensitivity to E09 is markedly
increased by exposure to drug in the absence of air. In
contrast, cell lines with high levels of DT-diaphorase show
little increase in sensitivity to E09 under hypoxic conditions.
As a consequence, the degree of sensitisation is inversely
proportional to the cellular activity of DT-diaphorase (Figure
3). More importantly, we have shown for the first time that
under hypoxic conditions the correlation is reversed such that
DT-diaphorase appears to protect cells from the cellular
toxicity of E09 (Figure 4b).
It is apparent from this panel of tumour cell lines that
activities of DT-diaphorase vary widely (Table II), but it is
not known if this is a true reflection of the activities present
in the tumours from which the lines were derived. Activities
are uniformly low in all the small-cell lung cancer cell lines,
but cell lines with low activities were present in each of the
tumour types. The difference between small-cell and non-
small-cell lung cancer cell lines has been reported previously,
and this did seem to reflect activities observed in lung tumour
samples (Malkinson et al., 1992). There was a much smaller
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Figure 4 DT-diaphorase activity and sensitivity to E09 in the
presence (0) and absence (0) of dicoumarol (200 iM) deter-
mined under both aerobic (a)and hypoxic (b) conditions. Results
are shown for the four pairs of cell lines and are those presented
in Table III.
range of activities of the two one-electron reducing enzymes
(Table II). The cell lines showed a wide range of sensitivities
to SR 4233, BCNU and cisplatin, but these sensitivities did
not relate to the activities of any of the three enzyme studied.
This is not surprising for BCNU and cisplatin since there is
no evidence that for cytotoxicity these agents require
metabolic activation. The benzotriazine di-N-oxide SR 4233
(tirapazamine) is a poor substrate for DT-diaphorase, and
two-electron reduction has been proposed to inactivate this
bioreductive agent (Walton & Workman, 1990; Brown,
1991). The lack of a correlation between DT-diaphorase
activity and sensitivity to SR 4233 suggests that DT-
diaphorase does not play a major role in the cellular
detoxification of this drug, and this supports our previous
observation (Plumb & Workman, 1994). In contrast, the
present results suggest that DT-diaphorase plays a key role in
the aerobic cytotoxicity of E09, and this supports previous
observations (Phillips et al., 1992; Robertson et al., 1992;
Walton et al., 1992; Plumb & Workman, 1994; Smitskamp-
Wilms et al., 1994).
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Figure 5 Possible routes of bioactivation of E09 to DNA reactive species by one- and two-electron reducing enzymes.
It is thought that one-electron reduction of E09 results in
the production of a semiquinone free radical (Figure 5). In
air it would be expected that this radical is rapidly back-
oxidised with the production of oxygen radicals which,
although toxic, can be removed by cellular detoxifying
enzymes. However, rapid redox cycling itself can cause cell
death owing to depletion of reduced co-factors (Workman,
1992). Two-electron reduction of quinones by DT-diaphorase
is thought to produce a potentially more stable hydroquinone
(Pan et al., 1984), and for E09 it has been proposed that this
can alklyate DNA, giving rise to DNA strand breaks and
cross-links which have been reported (Walton et al., 1991;
Bailey et al., 1994a). From a chemical perspective, either one-
or two-electron reduction would be predicted to activate
electrophilic sites in the E09 molecule. It would be expected
that cell lines will differ in their ability to withstand DNA
damage, and this is reflected in the range of sensitivities to
cisplatin and to the alkylating agent BCNU (Table II). In
view of this additional source of variability, it is perhaps
surprising that such a clear correlation between DT-dia-
phorase activity and E09 sensitivity is observed (Figure 1)
unless toxicity is related not to specific DNA adduct forma-
tion but to some other type of DNA damage such as strand
breaks. Two cell lines (A2780 and U251) are more sensitive
to E09 than would be predicted from DT-diaphorase activ-
ities alone. However, these cell lines are also very sensitive to
the other three drugs used, which suggests that they may be
inherently sensitive to DNA-damaging agents (Table II).
A number of agents, including cytotoxic drugs, are known
to induce expression of DT-diaphorase (Prochaska &
Talalay, 1988), and it might be expected that cell lines made
drug resistant in vitro would show increased activity. This is
true for the doxorubicin (2780AD)- and cisplatin (2780CP)-
resistant ovarian cell lines, and the results are consistent with
the observed decrease in aerobic sensitivity to E09 (Table II).
However, the elevation appears to be specific to this model
since the doxorubicin-resistant small-cell lung cancer
(H69LX10) cell line does not show increased activity of
DT-diaphorase and the breast cell line MCF7/Adr has a
marked decrease in activity which is associated with a reduc-
tion in sensitivity to E09 (Table II).
In order to compare the relative roles of DT-diaphorase
and hypoxia in the metabolic activation of E09, we selected
four representative pairs of cell lines from the panel. The cell
lines with the highest and lowest activities of DT-diaphorase
from each tumour type were used. DT-diaphorase activity is
commonly determined with the natural quinone menadione
as the substrate. However, we had two concerns with respect
to the sole reliance on using menadione as the substrate in
these studies. Firstly, while menadione is a good substrate for
DT-diaphorase from both rat and human, E09 is a better
substrate for the rat enzyme (Walton et al., 1991). Secondly,
these cell lines are all derived from tumours and genetic
mutations are known to alter the catalytic behaviour of the
enzyme (Chen et al., 1992; Ma et al., 1992). Thus, for these
eight cell lines DT-diaphorase activity was determined with
E09 as well as menadione as the substrate. In all cases
activity was higher for menadione than E09 (Table III).
However, although the relative activities when comparing cell
lines showed some variability depending on the substrate
used, the overall rank order was not changed (Figure 2).
In contrast to the one-electron reduction reaction, the
two-electron reduction reaction catalysed by DT-diaphorase
is generally regarded as oxygen independent. Hence, E09 can
be metabolised by both one- and two-electron reduction
reactions, but the balance between these pathways will be
determined by both the relative activities of one- and two-
electron reducing enzymes and by the presence or absence of
oxygen (Figure 5). Our results suggest that both pathways
are important in the activation of E09 since the degree of
enhancement of cytotoxicity under hypoxic conditions is
related to the cellular activity of DT-diaphorase (Figure 3).
Thus, in cell lines with high levels of DT-diaphorase activity
E09 is activated to a cytotoxic species in air (Table III). In
contrast, in cell lines with low levels of DT-diaphorase little
activation is observed in air but E09 can be activated by
one-electron reduction under hypoxic conditions. This sup-
ports our previous observations with the pair of colon car-
cinoma cell lines in which a substantial increase in sensitivity
to E09 under hypoxic conditions was observed only in the
BE cell line, which lacked DT-diaphorase activity (Plumb &
Workman, 1994). Although E09 is not as good as mena-
dione as a substrate for DT-diaphorase (Table III), this
enzyme appears to be a potent activator of E09 in cells since
the large hypoxic sensitisation ratios are only observed in cell
lines with negligible levels of activity such as BE (Plumb &
Workman, 1994) or MDAMB231 (Table III). This may be
an important observation in terms of potential toxicity to
normal tissues. Although DT-diaphorase activity may be
elevated in tumours it is possible that levels in some normal
tissues are already sufficient for significant aerobic activation
of E09.1142 J.A. PLUMB et al.
Our results show that, in contrast to the aerobic situation,
under hypoxic conditions sensitivity to E09 is inversely cor-
related with DT-diaphorase activity such that the cell lines
with the highest levels of DT-diaphorase are the least sen-
sitive (Figure 4b). The implication is that DT-diaphorase
protects from the hypoxic toxicity of E09, and this is sup-
ported by the observation that this protection is lost in the
presence of dicoumarol, an inhibitor of DT-diaphorase.
There are problems associated with the use of dicoumarol as
a specific inhibitor of DT-diaphorase since it is known to
have other effects including inhibition of cytochrome b5
reductase (Komiyama et al., 1982; Workman et al., 1989).
Enhanced hypoxic toxicity of mitomycin C in the presence of
dicoumarol has been observed (Keyes et al., 1985), and it was
suggested that this was due to increased activity of xanthine
dehydrogenase, which catalyses a two-electron reduction
reaction (Gustafson & Pritsos, 1992; Bizanek et al., 1993).
The clear correlation between sensitivity to E09 and activity
of DT-diaphorase in air indicates that xanthine dehydro-
genase makes a negligible contribution to the activation of
E09 unless it shows the same activity profile as DT-dia-
phorase. Dicoumarol decreased the aerobic toxicity of E09
(Figure 4a), which suggests that in air at least the major
effect is inhibition of DT-diaphorase. Furthermore,
dicoumarol increased the hypoxic toxicity of E09 in DT-
diaphorase-rich HT29 cells but not BE cells, which express a
mutant enzyme that lacks detectable activity (Plumb &
Workman, 1994), and in both cell lines activity of xanthine
oxidase is undetectable (Siegel et al., 1990). Xanthine dehy-
drogenase is probably the major form of the enzyme in cells
but it is rapidly converted to one-electron reducing xanthine
oxidase on isolation (Gustafson & Pritsos, 1992). We do not
think that increased activity of xanthine dehydrogenase
accounts for the increased hypoxic toxicity of E09 but sug-
gest that dicoumarol overcomes the previously unreported
protective effects of DT-diaphorase.
Although our results indicate a role for DT-diaphorase in
the aerobic toxicity of E09, it is not necessarily the hydro-
quinone that is responsible for the observed aerobic toxicity.
E09 shows significant toxicity in air even in cell line BE,
which lacks DT-diaphorase activity. This suggests either that
the parent drug is itself cytotoxic or that generation of drug
or oxygen radicals through one-electron reduction makes a
significant contribution to cell kill. We have shown that even
a small activity of DT-diaphorase significantly increases the
aerobic cytotoxicity of E09 (H187 and H128 cf H69, Table
II). It is unlikely that low activities will rapidly deplete the
pool of parent drug in cells, and this observation would
argue in favour of toxicity being due to metabolism of the
drug. The hydroquinone product of DT-diaphorase activity
can, in theory, be back-oxidised, via the semiquinone, to E09
in air but not under hypoxic conditions (Figure 5). Since
DT-diaphorase is protective under hypoxic conditions, this
suggests that the hydroquinone is less toxic than the semi-
quinone, and this has also been proposed for mitomycin C
(Dulhanty & Whitmore, 1991). From a chemical perspective
it might be predicted that formation of the semiquinone free
radical would activate the aziridine group together with the
two alkylating vinylogous side chains more effectively than
would be the case for the hydroquinone metabolite. How-
ever, our results would also support the proposal that the
hydroquinone is not cytotoxic and that aerobic toxicity is the
result of oxygen radical formation and transient appearance
of the semiquinone. This is supported by the identification by
electron spin resonance of a drug-based free radical, pre-
sumably the semiquinone, when E09 is metabolised under
aerobic conditions by either cytochrome P450 reductase or
DT-diaphorase (Bailey et al., 1993). In addition, metabolism
of E09 by either DT-diaphorase or cytochrome P450 reduc-
tase has been shown to produce DNA strand breaks (Walton
et al., 1991; Bailey et al., 1994b). We propose that, since in
this panel of cell lines activities of the one-electron reducing
enzymes are generally low compared with that of DT-dia-
phorase substantial formation and persistence of the semi-
quinone will only occur in those with sufficient DT-dia-
phorase activity. Although the semiquinone is unstable in air
the 1,000-fold hypoxic sensitisation ratio reported for BE
(Plumb & Workman, 1994) and the 757-fold ratio for the
breast cell line MDAMB231 reported here indicates that the
semiquinone must be a highly potent cytotoxin.
Given the very promising preclinical and early clinical
results seen with E09 it is clearly important to understand
the mechanisms involved, in the activation of the drug.
Agents such as SR 4233 that are activated only under
hypoxic conditions have limited use as single agents since
they target a small subpopulation of the tumour. Because
E09 is activated by both one- and two-electron reduction, it
can potentially target both aerobic and hypoxic areas of the
tumour. However, if DT-diaphorase protects hypoxic cells
from the toxicity of E09 the drug cannot be used to target
both oxic and hypoxic areas of the same tumour.
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